Wednesday, January 26, 2022 11:55:54 AM
How about over-alottment too? You keep making generalized statements about discounted share prices but we've all read the s-1 and know what the "dilution" to "the offering" buyers will be. What is this "discount" you speak of? Do you have links or ANYTHING substantial to back up these claims or is it just your opinion?
Recent SBFM News
- Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R) • ACCESS Newswire • 06/01/2026 12:00:00 PM
- Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology • ACCESS Newswire • 05/29/2026 12:00:00 PM
- Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing • ACCESS Newswire • 05/28/2026 01:00:00 PM
- Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin • ACCESS Newswire • 05/21/2026 11:00:00 AM
- Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering • ACCESS Newswire • 05/19/2026 04:05:00 PM
- Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering • ACCESS Newswire • 05/18/2026 04:15:00 PM
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
